Treatment of Multidrug-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem-Susceptible VAP
We prospectively evaluated the efficacy and toxicity of intravenously administered colistin in 35 episodes of ventilator-associated pneumonia (VAP) due to multidrug-resistant Acinetobacter baumannii. Microbiological diagnosis was performed with use of quantitative culture. In 21 patients, the episod...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2003-05, Vol.36 (9), p.1111-1118 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1118 |
|---|---|
| container_issue | 9 |
| container_start_page | 1111 |
| container_title | Clinical infectious diseases |
| container_volume | 36 |
| creator | Garnacho-Montero, J. Ortiz-Leyba, C. Jiménez-Jiménez, F. J. Barrero-Almodóvar, A. E. García-Garmendia, J. L. Bernabeu-Wittell, M. Gallego-Lara, S. L. Madrazo-Osuna, J. |
| description | We prospectively evaluated the efficacy and toxicity of intravenously administered colistin in 35 episodes of ventilator-associated pneumonia (VAP) due to multidrug-resistant Acinetobacter baumannii. Microbiological diagnosis was performed with use of quantitative culture. In 21 patients, the episodes were caused by a strain susceptible exclusively to colistin (the CO group) and were all treated with this antimicrobial intravenously. In 14 patients, the episodes were caused by strains that remained susceptible to imipenem and were treated with imipenem-cilastatin (the IM group). Acute Physiology and Chronic Health Evaluation II scores at the time of admission and Sequential Organ Failure Assessment scores at time of diagnosis were similar in both groups. VAP was considered clinically cured in 57% of cases in both groups. In-hospital mortality rates were 61.9% in the CO group and 64.2% in the IM group, and the VAP-related mortality rates were 38% and 35.7%, respectively. Four patients in the CO group and 6 in the IM group developed renal failure. Neurophysiological evaluation was performed during 12 episodes in the CO group, but it revealed no signs of neuromuscular blockade. Intravenous colistin appears to be a safe and effective alternative to imipenem for the management of VAP due to carbapenem-resistant strains of A. baumannii. |
| doi_str_mv | 10.1086/374337 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_18870034</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4483455</jstor_id><oup_id>10.1086/374337</oup_id><sourcerecordid>4483455</sourcerecordid><originalsourceid>FETCH-LOGICAL-c421t-866bdb686a8c0d7a9bb097ad660bd8462d0ebbdf87638b128d11a01adca6f3a63</originalsourceid><addsrcrecordid>eNp1kstu1TAQhiMEohfgCRAyiyJYBOzjxHbYRUfQU6kVFZQKsYnGl4BLYgfb4fI-PChGiXpWrDzy__mf0fwuikcEvyRYsFeUV5TyO8UhqSkvWd2Qu7nGtSgrQcVBcRTjDcaECFzfLw7IhmcOV4fFn6tgII3GJeR7dDEPyeowfynfm2hjgnzdKutM8hJUMgFJmEdwzlp0nd_YAZIPZRujVxaS0ejSmXn0zgJ6ft1evkA_bfqKzlwK8MM4P0e09UM2tu41anM9ThBs9G7lRjsZZ8bywxyVmZKVg0HZ5kFxr4chmofreVx8fPvmarsrz9-dnm3b81JVG5JKwZjUkgkGQmHNoZESNxw0Y1hqUbGNxkZK3QvOqJBkIzQhgAloBaynwOhx8WzxnYL_PpuYutHmQYYBnMmzd0QIjjGt9qAKPsZg-m4KdoTwuyO4-5dHt-SRwSer4yxHo_fYGkAGTlYAooKhD-CUjXuu4k3VCJG5pwvn5-n_zR4vzE3MqdxSVf4BVV1nuVzkvH_z61aG8K1jnPK623363O1OyQUmjHaM_gWCs7dr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>18870034</pqid></control><display><type>article</type><title>Treatment of Multidrug-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem-Susceptible VAP</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Garnacho-Montero, J. ; Ortiz-Leyba, C. ; Jiménez-Jiménez, F. J. ; Barrero-Almodóvar, A. E. ; García-Garmendia, J. L. ; Bernabeu-Wittell, M. ; Gallego-Lara, S. L. ; Madrazo-Osuna, J.</creator><creatorcontrib>Garnacho-Montero, J. ; Ortiz-Leyba, C. ; Jiménez-Jiménez, F. J. ; Barrero-Almodóvar, A. E. ; García-Garmendia, J. L. ; Bernabeu-Wittell, M. ; Gallego-Lara, S. L. ; Madrazo-Osuna, J.</creatorcontrib><description>We prospectively evaluated the efficacy and toxicity of intravenously administered colistin in 35 episodes of ventilator-associated pneumonia (VAP) due to multidrug-resistant Acinetobacter baumannii. Microbiological diagnosis was performed with use of quantitative culture. In 21 patients, the episodes were caused by a strain susceptible exclusively to colistin (the CO group) and were all treated with this antimicrobial intravenously. In 14 patients, the episodes were caused by strains that remained susceptible to imipenem and were treated with imipenem-cilastatin (the IM group). Acute Physiology and Chronic Health Evaluation II scores at the time of admission and Sequential Organ Failure Assessment scores at time of diagnosis were similar in both groups. VAP was considered clinically cured in 57% of cases in both groups. In-hospital mortality rates were 61.9% in the CO group and 64.2% in the IM group, and the VAP-related mortality rates were 38% and 35.7%, respectively. Four patients in the CO group and 6 in the IM group developed renal failure. Neurophysiological evaluation was performed during 12 episodes in the CO group, but it revealed no signs of neuromuscular blockade. Intravenous colistin appears to be a safe and effective alternative to imipenem for the management of VAP due to carbapenem-resistant strains of A. baumannii.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/374337</identifier><identifier>PMID: 12715304</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Acinetobacter baumannii ; Acinetobacter baumannii - drug effects ; Acinetobacter Infections - complications ; Acinetobacter Infections - drug therapy ; Acinetobacter Infections - microbiology ; Anti-Bacterial Agents - therapeutic use ; Antibacterial agents ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Antimicrobials ; Biological and medical sciences ; Colistin - therapeutic use ; Drug Resistance, Multiple ; Female ; Humans ; Imipenem - therapeutic use ; Infections ; Infusions, Intravenous ; Intensive care units ; Major Articles ; Male ; Medical sciences ; Middle Aged ; Mortality ; Pharmacology. Drug treatments ; Pneumonia ; Pneumonia - complications ; Pneumonia - drug therapy ; Pneumonia - microbiology ; Prospective Studies ; Renal Insufficiency - etiology ; Sepsis ; Septic shock ; Ventilator associated pneumonia ; Ventilators, Mechanical</subject><ispartof>Clinical infectious diseases, 2003-05, Vol.36 (9), p.1111-1118</ispartof><rights>Copyright 2003 The Infectious Diseases Society of America</rights><rights>2003 by the Infectious Diseases Society of America 2003</rights><rights>2003 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c421t-866bdb686a8c0d7a9bb097ad660bd8462d0ebbdf87638b128d11a01adca6f3a63</citedby><cites>FETCH-LOGICAL-c421t-866bdb686a8c0d7a9bb097ad660bd8462d0ebbdf87638b128d11a01adca6f3a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4483455$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4483455$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14794988$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12715304$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garnacho-Montero, J.</creatorcontrib><creatorcontrib>Ortiz-Leyba, C.</creatorcontrib><creatorcontrib>Jiménez-Jiménez, F. J.</creatorcontrib><creatorcontrib>Barrero-Almodóvar, A. E.</creatorcontrib><creatorcontrib>García-Garmendia, J. L.</creatorcontrib><creatorcontrib>Bernabeu-Wittell, M.</creatorcontrib><creatorcontrib>Gallego-Lara, S. L.</creatorcontrib><creatorcontrib>Madrazo-Osuna, J.</creatorcontrib><title>Treatment of Multidrug-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem-Susceptible VAP</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>We prospectively evaluated the efficacy and toxicity of intravenously administered colistin in 35 episodes of ventilator-associated pneumonia (VAP) due to multidrug-resistant Acinetobacter baumannii. Microbiological diagnosis was performed with use of quantitative culture. In 21 patients, the episodes were caused by a strain susceptible exclusively to colistin (the CO group) and were all treated with this antimicrobial intravenously. In 14 patients, the episodes were caused by strains that remained susceptible to imipenem and were treated with imipenem-cilastatin (the IM group). Acute Physiology and Chronic Health Evaluation II scores at the time of admission and Sequential Organ Failure Assessment scores at time of diagnosis were similar in both groups. VAP was considered clinically cured in 57% of cases in both groups. In-hospital mortality rates were 61.9% in the CO group and 64.2% in the IM group, and the VAP-related mortality rates were 38% and 35.7%, respectively. Four patients in the CO group and 6 in the IM group developed renal failure. Neurophysiological evaluation was performed during 12 episodes in the CO group, but it revealed no signs of neuromuscular blockade. Intravenous colistin appears to be a safe and effective alternative to imipenem for the management of VAP due to carbapenem-resistant strains of A. baumannii.</description><subject>Acinetobacter baumannii</subject><subject>Acinetobacter baumannii - drug effects</subject><subject>Acinetobacter Infections - complications</subject><subject>Acinetobacter Infections - drug therapy</subject><subject>Acinetobacter Infections - microbiology</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Antimicrobials</subject><subject>Biological and medical sciences</subject><subject>Colistin - therapeutic use</subject><subject>Drug Resistance, Multiple</subject><subject>Female</subject><subject>Humans</subject><subject>Imipenem - therapeutic use</subject><subject>Infections</subject><subject>Infusions, Intravenous</subject><subject>Intensive care units</subject><subject>Major Articles</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Mortality</subject><subject>Pharmacology. Drug treatments</subject><subject>Pneumonia</subject><subject>Pneumonia - complications</subject><subject>Pneumonia - drug therapy</subject><subject>Pneumonia - microbiology</subject><subject>Prospective Studies</subject><subject>Renal Insufficiency - etiology</subject><subject>Sepsis</subject><subject>Septic shock</subject><subject>Ventilator associated pneumonia</subject><subject>Ventilators, Mechanical</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kstu1TAQhiMEohfgCRAyiyJYBOzjxHbYRUfQU6kVFZQKsYnGl4BLYgfb4fI-PChGiXpWrDzy__mf0fwuikcEvyRYsFeUV5TyO8UhqSkvWd2Qu7nGtSgrQcVBcRTjDcaECFzfLw7IhmcOV4fFn6tgII3GJeR7dDEPyeowfynfm2hjgnzdKutM8hJUMgFJmEdwzlp0nd_YAZIPZRujVxaS0ejSmXn0zgJ6ft1evkA_bfqKzlwK8MM4P0e09UM2tu41anM9ThBs9G7lRjsZZ8bywxyVmZKVg0HZ5kFxr4chmofreVx8fPvmarsrz9-dnm3b81JVG5JKwZjUkgkGQmHNoZESNxw0Y1hqUbGNxkZK3QvOqJBkIzQhgAloBaynwOhx8WzxnYL_PpuYutHmQYYBnMmzd0QIjjGt9qAKPsZg-m4KdoTwuyO4-5dHt-SRwSer4yxHo_fYGkAGTlYAooKhD-CUjXuu4k3VCJG5pwvn5-n_zR4vzE3MqdxSVf4BVV1nuVzkvH_z61aG8K1jnPK623363O1OyQUmjHaM_gWCs7dr</recordid><startdate>20030501</startdate><enddate>20030501</enddate><creator>Garnacho-Montero, J.</creator><creator>Ortiz-Leyba, C.</creator><creator>Jiménez-Jiménez, F. J.</creator><creator>Barrero-Almodóvar, A. E.</creator><creator>García-Garmendia, J. L.</creator><creator>Bernabeu-Wittell, M.</creator><creator>Gallego-Lara, S. L.</creator><creator>Madrazo-Osuna, J.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>C1K</scope></search><sort><creationdate>20030501</creationdate><title>Treatment of Multidrug-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem-Susceptible VAP</title><author>Garnacho-Montero, J. ; Ortiz-Leyba, C. ; Jiménez-Jiménez, F. J. ; Barrero-Almodóvar, A. E. ; García-Garmendia, J. L. ; Bernabeu-Wittell, M. ; Gallego-Lara, S. L. ; Madrazo-Osuna, J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c421t-866bdb686a8c0d7a9bb097ad660bd8462d0ebbdf87638b128d11a01adca6f3a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Acinetobacter baumannii</topic><topic>Acinetobacter baumannii - drug effects</topic><topic>Acinetobacter Infections - complications</topic><topic>Acinetobacter Infections - drug therapy</topic><topic>Acinetobacter Infections - microbiology</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Antimicrobials</topic><topic>Biological and medical sciences</topic><topic>Colistin - therapeutic use</topic><topic>Drug Resistance, Multiple</topic><topic>Female</topic><topic>Humans</topic><topic>Imipenem - therapeutic use</topic><topic>Infections</topic><topic>Infusions, Intravenous</topic><topic>Intensive care units</topic><topic>Major Articles</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Mortality</topic><topic>Pharmacology. Drug treatments</topic><topic>Pneumonia</topic><topic>Pneumonia - complications</topic><topic>Pneumonia - drug therapy</topic><topic>Pneumonia - microbiology</topic><topic>Prospective Studies</topic><topic>Renal Insufficiency - etiology</topic><topic>Sepsis</topic><topic>Septic shock</topic><topic>Ventilator associated pneumonia</topic><topic>Ventilators, Mechanical</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garnacho-Montero, J.</creatorcontrib><creatorcontrib>Ortiz-Leyba, C.</creatorcontrib><creatorcontrib>Jiménez-Jiménez, F. J.</creatorcontrib><creatorcontrib>Barrero-Almodóvar, A. E.</creatorcontrib><creatorcontrib>García-Garmendia, J. L.</creatorcontrib><creatorcontrib>Bernabeu-Wittell, M.</creatorcontrib><creatorcontrib>Gallego-Lara, S. L.</creatorcontrib><creatorcontrib>Madrazo-Osuna, J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Environmental Sciences and Pollution Management</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garnacho-Montero, J.</au><au>Ortiz-Leyba, C.</au><au>Jiménez-Jiménez, F. J.</au><au>Barrero-Almodóvar, A. E.</au><au>García-Garmendia, J. L.</au><au>Bernabeu-Wittell, M.</au><au>Gallego-Lara, S. L.</au><au>Madrazo-Osuna, J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment of Multidrug-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem-Susceptible VAP</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2003-05-01</date><risdate>2003</risdate><volume>36</volume><issue>9</issue><spage>1111</spage><epage>1118</epage><pages>1111-1118</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>We prospectively evaluated the efficacy and toxicity of intravenously administered colistin in 35 episodes of ventilator-associated pneumonia (VAP) due to multidrug-resistant Acinetobacter baumannii. Microbiological diagnosis was performed with use of quantitative culture. In 21 patients, the episodes were caused by a strain susceptible exclusively to colistin (the CO group) and were all treated with this antimicrobial intravenously. In 14 patients, the episodes were caused by strains that remained susceptible to imipenem and were treated with imipenem-cilastatin (the IM group). Acute Physiology and Chronic Health Evaluation II scores at the time of admission and Sequential Organ Failure Assessment scores at time of diagnosis were similar in both groups. VAP was considered clinically cured in 57% of cases in both groups. In-hospital mortality rates were 61.9% in the CO group and 64.2% in the IM group, and the VAP-related mortality rates were 38% and 35.7%, respectively. Four patients in the CO group and 6 in the IM group developed renal failure. Neurophysiological evaluation was performed during 12 episodes in the CO group, but it revealed no signs of neuromuscular blockade. Intravenous colistin appears to be a safe and effective alternative to imipenem for the management of VAP due to carbapenem-resistant strains of A. baumannii.</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>12715304</pmid><doi>10.1086/374337</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2003-05, Vol.36 (9), p.1111-1118 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_18870034 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Acinetobacter baumannii Acinetobacter baumannii - drug effects Acinetobacter Infections - complications Acinetobacter Infections - drug therapy Acinetobacter Infections - microbiology Anti-Bacterial Agents - therapeutic use Antibacterial agents Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Antimicrobials Biological and medical sciences Colistin - therapeutic use Drug Resistance, Multiple Female Humans Imipenem - therapeutic use Infections Infusions, Intravenous Intensive care units Major Articles Male Medical sciences Middle Aged Mortality Pharmacology. Drug treatments Pneumonia Pneumonia - complications Pneumonia - drug therapy Pneumonia - microbiology Prospective Studies Renal Insufficiency - etiology Sepsis Septic shock Ventilator associated pneumonia Ventilators, Mechanical |
| title | Treatment of Multidrug-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia (VAP) with Intravenous Colistin: A Comparison with Imipenem-Susceptible VAP |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T15%3A50%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20of%20Multidrug-Resistant%20Acinetobacter%20baumannii%20Ventilator-Associated%20Pneumonia%20(VAP)%20with%20Intravenous%20Colistin:%20A%20Comparison%20with%20Imipenem-Susceptible%20VAP&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Garnacho-Montero,%20J.&rft.date=2003-05-01&rft.volume=36&rft.issue=9&rft.spage=1111&rft.epage=1118&rft.pages=1111-1118&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/374337&rft_dat=%3Cjstor_proqu%3E4483455%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=18870034&rft_id=info:pmid/12715304&rft_jstor_id=4483455&rft_oup_id=10.1086/374337&rfr_iscdi=true |